Identifier: KD01VVX
The technology is a novel method of disinfectant synthesis by the utilisation of cold atmospheric plasma (CAP) to generate sterile plasma-activated solutions (PAS). PAS will be an innovative alternative to address surface disinfection requirements being experienced during this pandemic, reducing the reliance of externally sourced disinfecting agents. The implementation of sustainable green technologies that reduce the impact of humans on the environment, such as CAP provides an efficient method of producing biocidal agents at low environmental costs.
Several recent studies have demonstrated the effectiveness of PAS as broad-spectrum biocidal agents. Their commercial application as disinfectants is limited by the need for toxicological assessment and accreditation as well as the production rate of producing PAS.
The technology consists of a new electronically controlled devise which may be used to produce PAS at a relatively high production rate. We managed to improve the reactor to process higher gas and liquid flow rates. The simplified and versatile design of the reactor allows for its rapid fabrication and up-scalability, through the inclusion of additional units operating in parallel or in series. We will also carry out toxicological assessment of plasma activated water on human skin using immortalised cell lines to obtain accreditation of PAS formulations for medical use.
The COVID-19 pandemic has highlighted the need and high-demand for broad-spectrum biocides. This would reduce shortages of disinfectant in places where they are not commonly available or when huge amounts are needed. The technology aims to certify PAS solutions for their use as a disinfectant in a domestic and medical setting, such as hospitals.
A prototype of a designed CAP reactor has been set up to generate PAS with selective antimicrobial properties. Further optimisation is required. Biocidal activity and dose-response experiments paired with toxicological risks are being carried out.
The technology contains proprietary solutions and components that are being considered for patenting.
We are looking for potential companies who are interested in collaborating on further developments.
Dr Jefferson de Oliveira Mallia